Loading…
Loading…
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Papa Johns (PJP Investments Group), has partnered with Blink to bring a mobile-first digital experience to its 1,300-strong workforce.
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
The Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and broader diversification than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has generated higher 1-year and 5-year total returns while maintaining lower price volatility.
The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return of 41% relative to 31% for the VanEck fund.
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
The State Street Health Care Select Sector SPDR ETF (XLV) offers significantly lower ownership costs, with an expense ratio of 0.08% compared to 0.58% for the Invesco Pharmaceuticals ETF (PJP). PJP provides concentrated exposure to 28 pharmaceutical stocks, while XLV holds 61 diversified healthcare companies.
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.